These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Past and present attempts to prevent radiocontrast nephropathy. Bailey SR Rev Cardiovasc Med; 2001; 2 Suppl 1():S14-8. PubMed ID: 12439363 [TBL] [Abstract][Full Text] [Related]
3. Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy. Stone GW; Tumlin JA; Madyoon H; Lepor NE; McCullough PA; Mathur VS; Murray PT; O'Neill WW Rev Cardiovasc Med; 2001; 2 Suppl 1():S31-6. PubMed ID: 12439366 [TBL] [Abstract][Full Text] [Related]
4. Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy. Asif A; Epstein DL; Epstein M J Clin Pharmacol; 2004 Dec; 44(12):1342-51. PubMed ID: 15545304 [TBL] [Abstract][Full Text] [Related]
5. Radiocontrast nephropathy: the dye is not cast. Lepor NE Rev Cardiovasc Med; 2000; 1(1):43-54. PubMed ID: 12457151 [TBL] [Abstract][Full Text] [Related]
7. [Nephropathy caused by radiocontrast media]. Kolarz M; Sułowicz W Przegl Lek; 2005; 62(5):292-8. PubMed ID: 16334535 [TBL] [Abstract][Full Text] [Related]
8. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients. Madyoon H Rev Cardiovasc Med; 2001; 2 Suppl 1():S26-30. PubMed ID: 12439365 [TBL] [Abstract][Full Text] [Related]
9. Pathophysiology of radiocontrast nephropathy and use of fenoldopam for its prevention. Mathur VS Rev Cardiovasc Med; 2001; 2 Suppl 1():S4-8. PubMed ID: 12439361 [TBL] [Abstract][Full Text] [Related]
11. [Contrast-induced acute renal failure]. Giannattasio M G Ital Nefrol; 2005; 22(3):217-25. PubMed ID: 16001365 [TBL] [Abstract][Full Text] [Related]
12. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Kini AA; Sharma SK Rev Cardiovasc Med; 2001; 2 Suppl 1():S19-25. PubMed ID: 12439364 [TBL] [Abstract][Full Text] [Related]
13. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Brienza N; Malcangi V; Dalfino L; Trerotoli P; Guagliardi C; Bortone D; Faconda G; Ribezzi M; Ancona G; Bruno F; Fiore T Crit Care Med; 2006 Mar; 34(3):707-14. PubMed ID: 16505657 [TBL] [Abstract][Full Text] [Related]
14. Effect of fenoldopam mesylate in critically ill patients at risk for acute renal failure is dose dependent. Samuels J; Finkel K; Gubert M; Johnson T; Shaw A Ren Fail; 2005; 27(1):101-5. PubMed ID: 15717642 [TBL] [Abstract][Full Text] [Related]
15. Contrast nephropathy: review focusing on prevention. Maeder M; Klein M; Fehr T; Rickli H J Am Coll Cardiol; 2004 Nov; 44(9):1763-71. PubMed ID: 15519005 [TBL] [Abstract][Full Text] [Related]
16. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ranucci M; Soro G; Barzaghi N; Locatelli A; Giordano G; Vavassori A; Manzato A; Melchiorri C; Bove T; Juliano G; Uslenghi MF Ann Thorac Surg; 2004 Oct; 78(4):1332-7; discussion 1337-8. PubMed ID: 15464494 [TBL] [Abstract][Full Text] [Related]
19. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine. Lepor NE Rev Cardiovasc Med; 2003; 4 Suppl 1():S15-20. PubMed ID: 12556733 [TBL] [Abstract][Full Text] [Related]